ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Three Genetics Pioneers Win Nobel Prize

October 11, 2002

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Henderson, Weinstein, Jukes to Present AACR Award Lectures

March 6, 1987

Report Questions Effectiveness Of Bimanual Pelvic Exam

March 31, 2006

In Brief: Pasche Named Director of Wake Forest Cancer Center

March 7, 2014

Penn Begins Clinical Trial Of A Vaccine For Breast Cancer Based On Telomerase

February 27, 2004